Key result
Narrative review underscores phenotype-based classification as a framework for personalized therapy in HFpEF.
Why the study?
Heart failure remains a leading cause of morbidity and mortality worldwide, characterized by rising prevalence and substantial heterogeneity in pathophysiology and treatment response.
Answers are grounded in this paper and cite their sources.
This review provides a comprehensive framework for understanding heart failure pathophysiology and highlights phenotype-based classification, particularly for HFpEF, to guide personalized therapy.
Heart failure (HF) remains a leading cause of morbidity and mortality worldwide, with rising prevalence and substantial heterogeneity in pathophysiology and treatment response. This narrative review focuses on chronic HF in adults, with emphasis on pathophysiological mechanisms and phenotype-based classification. This review provides a comprehensive analysis of the pathophysiology of heart failure, tracing the progression from baseline physiology to the complex mechanisms underlying heart failure. It begins by outlining normal cardiac function, detailing the structure and mechanical determinants of the left and right ventricles, including their helical myocardial fiber orientation, the phases of the cardiac cycle, and the role of torsion and diastolic recoil in maintaining efficient circulation. The review then delves into the pathogenesis of HF, highlighting the interplay among neurohumoral activation, structural remodeling, chronic inflammation, and cardiac aging. Furthermore, this review outlines the classification of HF based on left ventricular ejection fraction, distinguishing HF with preserved ejection fraction, reduced ejection fraction, and HF with mildly reduced ejection fraction. It particularly underscores the heterogeneity of HF with preserved ejection fraction, identifying distinct clinical phenotypes—specifically the metabolic, hypertensive, cardiorenal, pulmonary vascular, and inflammatory/autoimmune subtypes—each characterized by unique pathophysiological mechanisms that provide a framework for personalized therapy, with emerging agents beginning to show phenotype-specific efficacy.
No takes yet. Share an insight, caveat, or question.
A 2026 study conducted a review in Heart failure. This narrative review outlines heart failure pathophysiology and underscores phenotype-based classification, particularly for HFpEF, as a framework for personalized therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: